Portfolio Management & Research
Our firm is managed by a small group of executives with a track record of managing biotech businesses through the drug discovery and development process. We leverage our in-house knowledge and expertise in life sciences to provide a differentiated investment approach.
Prior to forming the General Partner, from June 2013 through October 2015, Tom managed Investor Relations at Pharmacyclics Inc., where he helped grow the company from a market cap of $6.74B to over $21B, which included the execution of one of the largest biotech acquisitions to date. Prior to Pharmacyclics, Inc., Tom spent 6 years as a medicinal chemist at Gilead Sciences Inc. engaging in novel drug design and drug development for HCV polymerase and protease inhibitors. Tom holds an M.B.A. from the University of California Los Angeles (2012) and a Master's degree in Organic Chemistry from the University of California Santa Barbara (2007). As a research scientist, Thomas Butler has been awarded numerous patents in the U.S. and internationally, as well as published in top academic journals such as the American Chemical Society Journal of Medicinal Chemistry.
Prior to forming Point Sur Investors, from 2008-2016, Ramses was with Pharmacyclics, Inc., a Nasdaq-listed biotech company. He began as Vice President, Finance & Administration, Corporate Secretary and acted as the Principal Financial and Accounting Officer. In that capacity he was responsible for accounting, SEC reporting, audits, and investor relations. He built and had operational responsibility for Finance, IT, HR, Legal, Facilities, Events. He later served as Executive Vice President of Corporate Affairs including Corporate Communications. Additionally, he structured and administered the international revenue for Pharmacyclics into a swiss-based subsidiary. He also actively participated in the final execution of key corporate milestones for Pharmacyclics, among them the Collaboration Agreement with J&J in 2011 (value $1.0 Billion) and the merger agreement with AbbVie in 2015 (value $21 Billion). Prior to Pharmacyclics, Ramses worked as an asset manager and investment banker, representing European and US institutional investors, family offices and high net worth investors. He began his career at Commerzbank, Germany, where he was an investment banker and portfolio manager for institutional international accounts. Ramses earned the Diplom Kaufmann degree, with honors, in Finance and Banking from the Westfaelische Wilhelms Universitaet Muenster, Germany.
ERIC SCHOENMAKERS, Ph.D.
Equity Research Senior Analyst
Eric most recently worked as an independent consultant providing services across his wide spectrum of expertise, including Preclinical R&D, Translational Medicine, Biomarker and CDx Development, and GxP/Quality Management. Before that he served as a Director Clinical Genetics within the Translational Medicine team at Pharmacyclics, Inc. Prior to joining Pharmacyclics, Eric headed the Pfizer Oncology Clinical Research Laboratory at Pfizer’s Global R&D site in La Jolla, CA. Eric started his career in academia, and was a tenured faculty member at the Department of Human Genetics in Nijmegen, The Netherlands for over a decade. He earned a MSc. in Biology (with majors in Molecular Biology, Genetics, and Immunology) at the University of Nijmegen, The Netherlands, and a summa cum laude doctorate in Human (Cancer) Genetics from the University of Leuven, Belgium. He has been awarded several US and international patents in the field of tumorigenesis and diagnostics, co-authored over a hundred peer-reviewed publications in top-tier international journals including Nature Genetics and the Journal of Clinical Oncology, and has been a scientific grant reviewer for over a dozen scientific organizations worldwide.
Equity Research Analyst
Thanaa is a recent addition to the Point Sur Team and a Class of 2018 graduate with a major in Finance and a minor in Applied Computing from San Jose State University (SJSU). Prior to joining Point Sur full time, Thanaa spent the last 18 months as a junior analyst at the firm conducting fundamental research on innovative public biotechnology firms. Prior to the internship, she served as the Founder and CEO of the Silicon Valley Fund, a student-managed investment fund at SJSU. Where she was responsible for managing over $30,000 in capital and a team of over 20 analysts. Thanaa also served as the President of the Banking and Investment Association, and the lead student organizer of the CFO Alumni Network Event at SJSU. Thanaa also currently serves as one of the founding board members at the Spartan Angel Network, a new SJSU based accelerator investing in innovative startups founded by SJSU students and alumni.
Equity Research Junior Analyst
Shipra joined the Point Sur Team in January of 2017 as an Equity Research Junior Analyst. Prior to joining Point Sur Investors, Shipra worked as a Business Intern at Wyoming Technology Business Center (2010) while pursuing her education at University of Wyoming (UW). Shipra has taken graduate level courses in Finance at UW and has cleared CFA level I. She holds an MBA from the UW (2008). Prior to UW, she served as a Project Executive conducting techno-economic evaluation, working with International clients and suppliers, at a Consulting firm in India. She earned her Bachelors in Engineering from India.
Equity Research Junior Analyst
Priyanka joined the Point Sur Team as a Summer Intern in June 2018 and now works as an Equity Research Junior Analyst. She has earned her Bachelor’s in Pharmacy and Master’s in Pharmacology from India and is currently pursuing a certificate course in “Clinical Trials Design and Management” from the UC Silicon Valley Extension, Santa Clara. She has over 6 years of Undergraduate and Graduate teaching experience in various subjects of Pharmacy and Pharmacology.
Copyright © 2015 Point Sur Investors LLC. All rights reserved.